Taro ElixSure “Spill-Resistant” Cough/Cold Medicines For Children Debut
This article was originally published in The Tan Sheet
Executive Summary
Taro Consumer Healthcare Products will back its new ElixSure line of cough/cold medicines for children with $22 mil. in promotional spending through 2004
You may also be interested in...
Taro Sees ElixSure Licensing As Means To Building Consumer Awareness
Taro Pharmaceuticals is continuing to pursue possible licensing arrangements for its ElixSure NonSpil technology, according to CFO Kevin Connelly
Taro Sees ElixSure Licensing As Means To Building Consumer Awareness
Taro Pharmaceuticals is continuing to pursue possible licensing arrangements for its ElixSure NonSpil technology, according to CFO Kevin Connelly
Taro Sees ElixSure Licensing As Means To Building Consumer Awareness
Taro Pharmaceuticals is continuing to pursue possible licensing arrangements for its ElixSure NonSpil technology, according to CFO Kevin Connelly